Metabolomics of bronchopulmonary dysplasia.

Piersigilli, Fiammetta;Bhandari, Vineet
(2020) Clinica Chimica Acta — Vol. 500, p. 109-114 (2020)

Files

2020_Piersigilli_Clin_Chim_Acta.pdf
  • Open Access
  • Adobe PDF
  • 406.72 KB
Download

Details

Authors
Abstract
The pathogenesis of Bronchopulmonary dysplasia (BPD) remains poorly understood. It is a multifactorial disease having a genetic-environmental basis. Although attempts have been made to identify a biomarker, none have been validated for clinical use to date. Metabolomics is a promising field of the "omics technologies" that could allow for better understanding of the pathogenesis and underlying mechanisms of BPD as well as facilitate detection of biomarkers. Identification of these biomarkers would improve diagnosis, identify patients in early disease stages and potentially target intervention. This review focuses on the evidence arising from metabolomics and its interaction with microbiomics and pharmacology with respect to pathogenesis and treatment options for this multifactorial complex disease.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Piersigilli, F., & Bhandari, V. (2020). Metabolomics of bronchopulmonary dysplasia. Clinica Chimica Acta, 500, 109-114. https://doi.org/10.1016/j.cca.2019.09.025 (Original work published 2020)